Long-term follow-up of clinical trial patients treated for chronic HCV infection with daclatasvir-based regimens.

ABSTRACT:

Background & aims

Daclatasvir has achieved high sustained virologic response (SVR) rates in diverse hepatitis C virus (HCV) populations. This study evaluated the long-term efficacy and safety of daclatasvir-based regimens administered during clinical studies.

Methods

Patients enrolled within 6 months of parent study completion or protocol availability at the study sites. The primary objective was durability of SVR at follow-up Week 12 (SVR12). Secondary objectives included analysing HCV sequences in non-responders or responders who relapsed, and characterization of liver disease progression.

Results

Between 24 February 2012 and 17 July 2015, this study enrolled and began following 1503 recipients of daclatasvir-based regimens (follow-up cut-off, 13 October 2015); 60%

SUBMITTER: Reddy KR 

PROVIDER: S-EPMC5947593 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature